May 2026 Biotech Catalysts to Watch
FDA decisions and clinical trial readouts expected in May 2026, each marked with what — if anything — a primary source confirms about it. FDA PDUFA dates with filing quotes live on the PDUFA calendar.
No date on this page has been confirmed against a primary source. Unsourced entries are AI-drafted from public information and can be wrong about whether an event is still upcoming; they are listed separately and show the expected window only. Verify against the FDA, the company, or ClinicalTrials.gov before acting on any of them. 2 of 7 link to the ClinicalTrials.gov record for the program behind them — the registry confirms that the program exists, not the date.
7 catalysts shown
Phase 3 CANOPY topline data for vosoritide in idiopathic short stature
Voxzogo (vosoritide) · Idiopathic short stature (ISS)
Program confirmed on ClinicalTrials.gov · 2026-09-05 · the date itself is unverified
Sponsor record: 13 of 70 late-stage studies registered by BioMarin Pharmaceutical were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
BioMarin tries to expand Voxzogo beyond achondroplasia into the much larger idiopathic short stature population. Approval would multiply the addressable market by 10x+ and rescue the franchise from disappointing achondroplasia uptake.
Primary endpoint is annualized growth velocity gain vs placebo. Phase 2 data was supportive. A successful readout could double the Voxzogo franchise's peak sales estimate.
AI-drafted context, not individually reviewed.
DESTINY-Breast09 Phase 3 OS update at ASCO 2026
Enhertu (trastuzumab deruxtecan) · 1L HER2+ metastatic breast cancer
Program confirmed on ClinicalTrials.gov · 2026-09-09 · the date itself is unverified
Why it matters
AZN and Daiichi present mature overall survival data for Enhertu in front-line HER2+ metastatic breast cancer at ASCO. Confirming an OS advantage over the THP regimen would entrench Enhertu as the new 1L standard of care.
Updated OS hazard ratio with longer follow-up. Even a modest OS benefit (HR <0.85) supports continued guideline adoption. Watch for cardiac and pulmonary safety updates.
AI-drafted context, not individually reviewed.
Unconfirmed watchlist
No primary source has been found for these yet. They are AI-drafted from public information, shown with the expected window rather than a day, and may already have happened or moved. Treat them as prompts to check the company's guidance, not as dates.
Phase 3 ATTAIN-1 topline data for orforglipron in obesity
Orforglipron · Obesity
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 93 of 1073 late-stage studies registered by Eli Lilly were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
First Phase 3 readout for Lilly's once-daily oral GLP-1, orforglipron. If it delivers meaningful weight loss without GI side effects worse than injectables, this becomes a $20B+ franchise and reshapes the obesity market overnight.
Phase 2 showed ~14.7% weight loss at 36 weeks. Phase 3 needs to confirm at 72 weeks while keeping discontinuation rates below 15%. Strong data sends LLY up 5-10%; weak data triggers competitive re-rating in Viking (VKTX), Structure (GPCR), and Terns (TERN).
AI-drafted context, not individually reviewed.
HARMONi-6 Phase 3 topline data for ivonescimab in 1L PD-L1+ NSCLC
Ivonescimab · First-line PD-L1+ non-small cell lung cancer
Unverified — date is AI-generated and has not been checked against a primary source.
Why it matters
Summit's PD-1xVEGF bispecific antibody faces its definitive Phase 3 readout in the first-line lung cancer setting versus Keytruda. The 2024 HARMONi-2 study suggested ivonescimab could beat Keytruda in PD-L1+ patients. HARMONi-6 is the global confirmation.
Statistically significant PFS benefit over Keytruda would be a paradigm shift in immuno-oncology and put SMMT on a $30B+ revenue trajectory. A miss or wash sends the stock down 40-60% and resets the entire PD-1xVEGF bispecific thesis.
AI-drafted context, not individually reviewed.
IMpactMF Phase 3 interim analysis for imetelstat in myelofibrosis
Rytelo (imetelstat) · JAK-inhibitor relapsed/refractory myelofibrosis
Unverified — date is AI-generated and has not been checked against a primary source.
Why it matters
Geron's first telomerase inhibitor is already approved in MDS. IMpactMF tests whether imetelstat can extend overall survival in myelofibrosis after JAK inhibitor failure — a setting with no approved options.
Survival hazard ratio below 0.7 would support an sNDA filing and approximately double the commercial opportunity for Rytelo. A wash would cap the asset at its current MDS-only ceiling.
AI-drafted context, not individually reviewed.
Phase 3 IGNYTE-3 Phase 3 topline data in PD-1 failed melanoma
RP1 (vusolimogene oncorepvec) · Anti-PD-1 failed advanced melanoma
Unverified — date is AI-generated and has not been checked against a primary source.
Why it matters
Replimune's oncolytic virus immunotherapy RP1 faces its definitive Phase 3 readout following the 2025 FDA CRL. A statistically robust ORR and DOR in the post-PD-1 melanoma setting clears the path back to FDA submission.
Phase 2 data showed 32-33% objective response rate. Phase 3 needs to confirm at least a 25% ORR with durable responses. Success doubles or triples REPL; failure caps the stock indefinitely.
AI-drafted context, not individually reviewed.
Amtagvi label expansion data update at ASCO 2026
Amtagvi (lifileucel) · Anti-PD-1 failed advanced melanoma; expansion into NSCLC
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 3 of 13 late-stage studies registered by Iovance Biotherapeutics were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Iovance presents updated TIL therapy data including the first meaningful Phase 2 NSCLC dataset. NSCLC expansion is critical to scaling TIL beyond a melanoma niche.
Watch for response rate, durability, and manufacturing success rate in NSCLC. A confirmed response rate above 20% with manageable safety would meaningfully expand IOVA's TAM.
AI-drafted context, not individually reviewed.
Market context
May 2026 is the heaviest catalyst month of the first half, anchored by the ASCO Annual Meeting in Chicago (May 29 - June 2). The XBI biotech index enters the month at year-to-date highs after a strong stretch of large-cap M&A and successful Phase 3 readouts. Macro tailwinds include the Fed's first 2026 rate cut and continued capital flow back into pre-revenue biotech. The obesity and oncology subsectors dominate the catalyst slate: orforglipron's Phase 3 readout is the single most-watched event in the global GLP-1 race, while ASCO 2026 will feature pivotal updates from Enhertu, Amtagvi, and multiple ADC and bispecific programs. Gene therapy faces another defining month with the Sarepta LGMD2E PDUFA, which the market will read as a referendum on FDA's continued tolerance for AAV gene therapy after the Elevidys saga. Expect outsized stock moves: small/mid-cap names like SMMT, REPL, and GERN have binary readouts that could swing 50-100%. PDUFA-driven names (MDGL, VRTX, SRPT) and large-cap LLY rounds out a month where investors who track the catalyst calendar can meaningfully outperform.
Conferences this period
ASCO Annual Meeting 2026
May 29 - June 2, 2026
ATS International Conference 2026
May 15-20, 2026
Sponsored
Trade upcoming biotech catalysts commission-free on WebullAffiliate link — we may earn a commission at no cost to you
Want one of these readouts explained in writing?
Name a catalyst from this calendar and get a written breakdown of what the trial actually measures, what success and failure look like, and where the endpoint, safety, and financing risk sits — in 3 business days, for $249.
Get the free May 2026 catalyst briefing
Receive the next weekly briefing with the biggest upcoming catalysts, date changes, and plain-English context.
Free weekly biotech briefing. No spam. We only use this address for the briefing. By subscribing, you agree to our Privacy Policy and Terms.
No financial advice. Educational research only. Affiliate links may earn compensation.